Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.

The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. 

United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.

The U.S. Food and Drug Administration’s PDUFA dates for the last week of November 2020 include a review of Liquidia Technologies’ NDA for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).

Gilead Sciences agreed to pay $97 million to resolve claims from the U.S. government that the company violated the False Claims Act.

Acceleron Pharma and Fulcrum Therapeutics enter 2020 as partners to tackle pulmonary diseases.

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.

Silver Spring, Maryland-based United Therapeutics announced that the company’ esuberaprost tablet did not meet the primary endpoint in the BEAT Phase III clinical trial in patients with pulmonary arterial hypertension (PAH).

A unit of Johnson & Johnson will pay $360 million to resolve an investigation into the company’s financial support of a charity that helped Medicare patients cover out-of-pocket drug costs.

Shares of Arena Pharmaceuticals rocketed more than 28 percent after the company signed a licensing agreement with United Therapeutics for a late-stage drug candidate. The deal could be worth more than $1.2 billion for Arena.